We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Easily understand and manage all your insurance in one simple app, ready for the digital age. Wrisk is all about transparency and allows customers to see how much they’re currently paying for their insurance, what actions they can take to reduce their risk and purchase the insurance seamlessly from within the app. Wrisk is seeking investment to expand and cater for as many insurance needs as possible. 
days to go: Expired investment: £1,044,630
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
A FCA-authorised and regulated digital credit card on smartphones, for those with modern and busy lifestyles. Jaja aims to offer a fair and transparent banking service that gives consumers greater confidence, control and freedom over their finances. The company has tested their app and card with Visa and has partnered with Asda to offer online credit instantly. Jaja's business model allows revenue to be generated via interest payments from revolving lines of credit. Two products will be offered to consumers; the Jaja Credit Card and Jaja Pay. Both will be suitable for B2B and B2C operations. Investments will be used to launch a beta round for 5,000 users to build a community before the products are publicly released. In addition, Jaja intends to expand its customer service team and produce marketing campaigns for their business.
days to go: Expired investment: £4,957,534
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go: Expired investment: £343,926
Byrd is a coaching platform that works around everyday life to keep people running. It asserts that its unique EQAI-coach uses 1 billion variables to coach people to their goal, whether that’s simply to remain healthy or to hit a specific event. The company estimates that 200 million people were running globally in 2018. It seeks to target this group and become a contender in a fitness market that is estimated to be worth $2.4 billion. The company has created and tested two beta versions of its Android and iOS apps. It points out that it has conducted surveys involving hundreds of runners clocking in 20,000 km of running and incorporated that data into its portal. Byrd argues that its app has been built on Google Cloud infrastructure and is ready to horizontally scale. It will use 40% of the investment in product evolution, 20% in acquisition, 23% towards marketing, and 17% towards enriching customer experience.
days to go: Expired investment: £266,836
AgeWage is a pension scoring system that provides customized information to the customers. By bringing together your pension pots, AgeWage scores each of the pension pot out of 100 and tells you how well they have worked for you. The scoring system offers information that helps the customer make decisions on how to consolidate pots, reinvest their money and most importantly, how to get their money back. The company has signed an MoU with Royal London to enter into B2B arrangements. It was also chosen for the Direct Support Innovate programme with the FCA. AgeWage has been voted the best new idea in the BGL partnership awards(2018). With its proceeds, the company is planning to invest in digital development, marketing the application to the general public and other organizations. Also, it is trying to build out the infrastructure to support the development of the product with third parties such as Annuity Providers, IFAs, and Drawdown Providers.
days to go: Expired investment: £317,760
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph